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Excipient’s SafetyAbstract Pharmaceutical excipients are no longer inert materials but it is effective and able to
improve the characteristics of the products’ quality, stability, functionality, safety, solubility and
acceptance of patients. It can interact with the active ingredients and alter the medicament charac-
teristics. The globalization of medicines’ supply enhances the importance of globalized good man-
ufacturing practice (GMP) requirements for pharmaceutical excipients. This review was intended to
assess the globalization status of good manufacturing practice (GMP) requirements for pharmaceu-
tical excipients. The review outcomes demonstrate that there is a lack of accurately deﬁned methods
to evaluate and measure excipients’ safety. Furthermore good manufacturing practice requirements
for excipients are not effectively globalized.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.Contents
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The word excipient comes from Latin name meaning to receive,
to gather or to take out (Pifferi and Restani, 2003). Interna-
tional Pharmaceutical Excipients Council (IPEC) deﬁned
excipients as the other substances in the pharmaceutical formu-
lation than the active pharmaceutical ingredients (API) which
have been appropriately evaluated for the safety in order to
help in processing, manufacturing, protection and give support
or to enhance stability, bioavailability or patient acceptability
or to assist in product identiﬁcation or improve any features
of the safety or effectiveness of the drug delivery system during
storage or use (Apte et al., 2003; Ahjel and Lupuliasa, 2008).
Excipient can be of animal origin such as stearic acid and gela-
tin, plant origin like starch and cellulose, mineral such as cal-
cium phosphate and silica or synthetically produced such as
polysorbates and povidone (Pifferi and Restani, 2003).
The basic requirements for pharmaceutical excipient in-
clude safety, functionality and quality (Pifferi and Restani,
2003). Regulatory layers have been implemented through the
regulatory bodies to ensure the positive impact of excipients
on the ﬁnal products’ safety, quality, effectiveness, functional-
ity and stability due to an increase in the percentage of coun-
terfeit medicines and gradually losses of patent protection. We
can conclude that importance of pharmaceutical excipients
encompasses three parts: functions, quality evaluation and
safety of pharmaceutical excipients. Toxicity and bioavailabil-
ity are the main problems of excipients regarding safety and
function requirements consequently.
Determination of optimum concentration in addition to
compatibility studies of excipients with active ingredients and
other excipients are required (U.S. Department of Health
and Human Services, 2006). Excipient can interact physically
with the active ingredient such as degradation of nitrazepam
due to the adsorption interaction with colloidal silica, or inter-
act chemically like incompatibility between hydrogen donating
drugs such as lansoprazole and famotidine with polyvinylpyr-
rolidone (Crowley and Martini, 2001).
The term globalization was ﬁrst used in 1940s. The political
economist George Modelski reintroduced the term in 1972 to
describe the impact of multinational cooperation on economic
relations within and between countries (Collins, 2003). The con-
cept of globalizations means that countries and regions of the
world come together toward policies and regulations (Abraham
and Reed, 2003). In other words it is a global network where
there is a better interconnection between different countries
and regions (Alasuutari, 2000). It dismantles the state barriers
to trade, economic, social and politics and help poor countries
to fasten their growth and reduce poverty (Srinivasan, 2002).
Globalization of pharmaceutical regulations helps in
removing the trade barriers, improving technical cooperation,
and increasing cost saving of testing and evaluation processes,
supporting free market competition and information transfor-
mation. Denmark, Finland, Norway and Sweden startedregional harmonization of pharmaceutical regulations by
adoption of Nordic pharmacopeia, then European pharmaco-
peia in 1964, followed by establishment of the European Med-
icine Evaluation Agency in 1996 and European pharmacopeia
commission (Wehrli, 1997). World Health Organization
(WHO) started the globalization of pharmaceutical regulations
by considering rational medicine use, medicine affordability,
ﬁnancial support of healthcare and an efﬁcient health and
medicine supply system (Chua et al., 2010), International Non-
proprietary (generic names) and International pharmacopeia.
Globalized good manufacturing practice requirements for
pharmaceutical excipients are crucial to face the impact of
globalized medicines’ supply. In fact no country is protected
from the globalization of medicines’ supply. For example in
2006 the United States of America which is a very developed
country received 145,000 line entries of imported drugs from
160 countries (Woo et al., 2008).
The study was intended to review the importance and glob-
alization status of good manufacturing practice requirements
for pharmaceutical excipients.
2. Method
Searching from Google scholar and science direct data base
was used as a method to review the articles related to the in-
tended subject. The searching focused on the modern role of
pharmaceutical excipients, the concept of globalization and
the regulatory status of good manufacturing practice for phar-
maceutical excipients.
3. Functions of excipients
Historically excipients are considered as inert materials. How-
ever, they are effective materials mainly to enhance the stabil-
ity of the formulation, release or absorption of the active
ingredients (Pifferi et al., 1999a,b). The largest group of excip-
ients in the pharmaceutical formulations is used to improve
solubility of the active ingredients as shown in Table 1 (Strick-
ley, 2004). Others are used as a disintegrant, binder, lubricant,
ﬁller agent to facilitate manufacturing of medicine and sweet-
ener to give a pleasant taste to patients as shown in Table 2
(Akers, 2002; Koizumi et al., 2004; Jivraj et al., 2000). Some
excipients are used for identiﬁcation and coloring agents. In
particular certain excipients have multiple functions. In fact
excipients may interact positively or adversely affect the for-
mulations especially in side living cells (Jackson et al., 2000).
This intensiﬁed sophistication of in vivo researches about drug
bioavailability using various excipients.
4. Evaluation of the pharmaceutical excipients’ quality
Shortage of testing strategies, protocols or guidelines affects
efﬁcient evaluation of excipients. One of the debates about
Table 1 Commonly used solubilizer excipients based on its functions.
No. PH modiﬁer Water soluble
organic
solvents
Water insoluble
organic solvents
Nonionic
surfactants
Water insoluble
lipids
(triglycerides)
Cyclodextrins Phospholipids
1 Citric acid Polyethylene glycol
300 & 400
Beeswax Cremphor Peanut oil a-cyclodextrins Glycerol
2 Tartaric acid Ethanol D-a tocopherol Tween 20 Corn oil b-cyclodextrins Choline
3 Benzoic acid Propylene glycol Oleic acid Tween 20 Soybean oil c-Cyclodextrins DSPG
4 Glycerin Mono & di
glycerides
Sorbitan
monooleate
(Span 20)
Sesame oil Sulfobutylether-cyclodextrin DMPC
5 N-methyl 2-pyrrolidone Peppermint oil Olive oil Hydroxypropyl-cyclodextrin DMPG
6 Dimethyl acetamide Polysorbate 20 & 80 Cotton seed oil
Adapted from: (Cornaire et al., 2004, Kornblum and Stoopak, 1973, Gohel and Jogani, 2005).
Importance and globalization status of good manufacturing practice (GMP) requirements 11excipient production is the difﬁculty of consistency which is
one of the fundamental issues in the GMP implementation,
other is the variation between test cost and proﬁt from such
industry (Moreton, 2006). But the studies assert the need for
excipient testing strategy (Baldrick, 2000). One example of that
is the impurity test for hydro peroxide (HPO) (Wasylaschuk
et al., 2007). Proxides are commonly available as impurities
in povidone, crospovidone and polysorbate (Crowley and
Martini, 2001). Qualiﬁcation of the suppliers is an efﬁcient
method to evaluate the quality of the excipients and combat-
ting the counterfeit materials (Chow et al., 2009) 1, 2. Toxicity
tests are used to evaluate pharmaceutical excipients such as
tolerance study and mucociliary clearance test (Ilium, 1998).
5. Pharmaceutical excipients’ safety
The use of some excipients results in many health problems.
Some of the excipients display toxicity effects on the kidneys,
neonates and gastrointestinal tract. Tragic events happened
due to the lack of excipient safety like E-ferol incident in the
United States of America in which many cases of infants died
due to intravenous administeration of vitamin E to premature
infants using polysorbate as an emulsifying agent in 1983 and
1984 to help in the treatment of retrolental ﬁbroplasia (RLF),
(Golightly et al., 1988) and a disaster occurred in Haiti in 1996
in which 90 people died due to mislabeling cough syrup (Stein-
berg et al., 2001). In 2009 another catastrophic event happened
in which twenty four children died in Bangladesh due to para-
cetamol syrup adulterated with ethylene glycol (Sheehan,
2010). All these events imposed the world to adopt regulations
for excipient to ensure quality and safety.
Pharmaceutical formulation consists of two categories of
ingredients, active materials and excipients. However, atten-
tion was paid to the active constituents to cause toxicity but
excipients elicited toxicity; as displayed in Table 3. Informa-
tion on the package of medicines should include excipients to
increase awareness of doctors, pharmacists and people on safe
use of excipients (Pifferi and Restani, 2003).
6. The globalization status of GMP requirements for
pharmaceutical excipients
GMP requirements for excipients include three main issues
safety, quality and functionality instead of efﬁcacy for theactive ingredients (Pifferi and Restani, 2003). The excipient
cost plays a crucial role on leading control measurements of
these requirements as the manufacturers seek to minimizing
the cost (Raﬁdison and Ulman, 2003). Progressing of new
excipients usage in the pharmaceutical formulations is slow
due to a lack of global speciﬁc guidance to assess and ensure
of its safety (Baldrick, 2010). On the other hand the pharma-
ceutical industry needs an innovation of excipients that can en-
hance the efﬁcacy and quality of the pharmaceutical
formulation (Ermens, 2004).
There are essential needs to assess the compatibility of the
currently used excipients to each other and their functionality
in the pharmaceutical formulation (Guideline, 2009).
Although the United States of America food and drug admin-
istration (FDA) arises the importance of excipient GMP com-
pliance in 2008, currently there are no global regulation
standards for excipients, in other words the regulations are
scattered despite the fact that drug authorities are trying to im-
prove the regulatory status of pharmaceutical excipients. For
instance in 2010 GMP certiﬁcate of quality management sys-
tem for silicon dioxide was adopted in Grace as the ﬁrst certif-
icate of excipient GMP conformance (Monsuur and Poncher,
2010).
Globalization of the medicine market motivates manufac-
turers especially in the developed countries to consider various
pharmacopeia requirements to facilitate exportation of their
products (Larner et al., 2006). In fact globalization of the ﬁn-
ished products’ supply chain elevated gradually even in the
developed countries, for example the United States Food
and Drug Administration (FDA) registered manufacturing
sites from China increase from 140 sites with 797 drug items
in 2001 to 815 registered sites of 3000 listed items (Woo
et al., 2008), so there is no country protected from this
globalization.
Moreover, the current situation needs globalization of the
excipients’ supply chain as well to improve the GMP compli-
ance and appropriately counteract counterfeit and substan-
dard ingredients besides lowering of the pharmaceutical
excipients’ cost (Sheehan, 2010) in addition to that traceability
and contamination control are fundamental elements and
should be revised by suppliers (Raﬁdison and Ulman, 2003).
There are three main bodies concern with pharmaceuitical
exicipents in the world as shown in Fig. 1. These organizations
are associations of producers, distributors and users.
Table 2 Other functions of pharmaceutical excipients.
Functions 1 2
Enhance absorption Chitosan D-a-tocopheryl polyethylene glycol 1000 succinate
Disintegration agent Microcrystalline cellulose Citric acid
Binding agent Corn starch Xanthane gum
Lubricant Magnesium stearate Stearic acid
Compaction ﬁller Sorbitol Mannitol
Compression ﬁller Granulated lactitol Crystalline maltose
Sweetener Acesulfame potassium Mannitol
Stability Polyvinylpyrollidone (Povidone) (PVP) Alginic acid
Antioxidant Butylated hydroxy toluene Sodium metabisulﬁte
Preservative Butyl paraben Sodium propoinate
Buﬀers Di sodium hydrogen phosphate Sodium citrate dihydrate
Filler diluents Lactose Microcrystalline cellulose
Adapted from: (Cornaire et al., 2004, Kornblum and Stoopak, 1973, Gohel and Jogani, 2005).
Table 3 Examples of pharmaceutical excipient toxicity.
Number Excipient Toxicity
1 Parenteral b-cyclodextrins Nephrotoxicity
2 Ethylene glycol Renal failure
3 Mannitol Osmotic diarrhea
4 Parabens & sodium metabisulﬁte Neonatal toxicity
5 Sulﬁting agents in asthmatic patients Sensitive to excipient toxicity
6 Doxapram Very low birth weight infants
7 Phenolic excipients Dermatitis, irritation and allergy
Adapted from: (Brewster and Loftsson, 2007, Osterberg and See, 2003, Lass et al., 2012, Golightly et al., 1988).
Figure 1 The biggest bodies concerned with pharmaceutical
excipient regulations.
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Due to incorporating of excipients in both the pharmaceutical
and food industries great attention is paid to the safety, quality
and functionality of excipients. This review suggests deﬁciency
in studies to measure excipients’ safety and a lack of effective
global work to adopt speciﬁc requirements on improving
pharmaceutical excipients’ standards, although of the efforts
to improve excipient regulations by the regulatory authorities.
However, the information and ﬁndings of numerous studies
prove that globalization for GMP requirements forpharmaceutical excipients is fundamental to counteract a neg-
ative impact of globalization of the medicines’ supply, enhance
GMP compliance, minimize pharmaceutical excipient cost,
maximize the degree of safety and quality and elevate stan-
dards of consumer protection to meet health care providers
and customers’ expectations.
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